Pharma Innovator Frenelle Launches; CEO Missling Attends JPM 2025

Pharma Innovator Frenelle Launches; CEO Missling Attends JPM 2025

Frenelle Pharma, a dynamic new player in the pharmaceutical industry, is proud to announce its official launch. The company is leveraging its proprietary Faros™ long-acting injectable technology to revolutionize healthcare solutions across both human and animal health. Building on the success of its first product, SX600, Frenelle Pharma is positioned to redefine the future of medicine with its cutting-edge platform.

Frenelle Pharma operates through three distinct subsidiaries, each focused on advancing healthcare in unique and impactful ways:

  1. Frenelle PBC: As a public benefit corporation, Frenelle PBC is dedicated to developing superior medications to address addiction. The goal is to maximize access and utilization of treatments by commercializing long-acting injectable drugs with a strong public health mission. Frenelle PBC recently announced an exciting collaboration with the Mayo Clinic, marking an important step in bringing its mission to life.
  2. SpineThera: A clinical-stage pharmaceutical company, SpineThera is focused on advancing SX600, a long-acting injectable treatment for lumbar radicular pain (commonly known as sciatica). SX600 has demonstrated best-in-class potential in Phase 2 clinical trials and is poised to offer a groundbreaking solution to patients suffering from this debilitating condition.
  3. Anumio: Specializing in animal health, Anumio is dedicated to advancing veterinary medicine. With a focus on innovative, long-acting treatments, Anumio aims to improve the care and welfare of pets, providing solutions that enhance the quality of life for animals and their owners.

Jeff Missling, CEO of Frenelle Pharma, highlighted the strategic approach behind the company’s growth: “Building on the success of SX600 in treating lumbar radicular pain, our team has identified numerous opportunities to expand the application of our Faros™ long-acting injectable technology. Our portfolio is organized into subsidiaries that are focused on specific therapeutic areas. We are committed to enhancing the effectiveness and durability of treatments while minimizing side effects. Above all, we remain focused on equitable access to healthcare, putting patients at the center of everything we do.”

Faros™ Technology: Transforming the Treatment Landscape

At the heart of Frenelle Pharma’s innovation is its proprietary Faros™ technology, which enables the precise, sustained delivery of medications. By reducing the frequency of doses while increasing their efficacy, Faros™ enhances patient compliance and reduces the burden of frequent administration. This platform has already shown its transformative potential, with SX600 serving as a key example of its success.

The Faros™ technology is micro-sized, smaller than red blood cells, allowing injections through very fine needles. This minimizes injection site pain and could improve the safety and effectiveness of soft tissue injections. Additionally, Faros™ has aerodynamic properties that could make it suitable for inhalation applications, further expanding its potential in diverse treatment areas.

Frenelle Pharma’s focus on advancing Faros™ technology aligns with its commitment to improving patient outcomes by developing treatments that are more effective and easier to use. The company is deeply invested in ensuring that its innovations are accessible to patients in need, particularly in underserved communities where access to healthcare can be a significant challenge.

Frenelle Pharma’s Participation at BIO 1:1 Partnering @ JPM 2025

As part of its official launch, Frenelle Pharma will participate in the BIO 1:1 Partnering event at the 2025 J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 13-16, 2025. This high-profile event will provide Frenelle Pharma with the opportunity to present its groundbreaking vision to investors, pharmaceutical leaders, and healthcare innovators. By engaging with strategic collaborators and stakeholders, the company aims to build strong partnerships that will accelerate its growth and impact in the healthcare space.

About Frenelle Pharma

Frenelle Pharma is a pioneering portfolio of companies focused on addressing critical healthcare challenges using its proprietary Faros™ long-acting injectable technology. The technology is designed to enable injections using very small gauge needles, reducing pain and discomfort associated with injections while improving the safety of soft tissue treatments. With applications ranging from addiction treatment to pain management and animal health, Frenelle Pharma is well-positioned to drive advancements in healthcare and improve lives.

Based in Medical Alley, Minnesota, a global hub for health innovation, Frenelle Pharma benefits from its location at the epicenter of healthcare research and development. With a commitment to scientific progress and patient-centered care, Frenelle Pharma is poised to make a lasting impact on both human and animal health.

Through its innovative subsidiaries and the development of Faros™ technology, Frenelle is leading the way in transforming the healthcare landscape, providing patients with better, longer-lasting treatments and improving the quality of life across multiple sectors. With an exciting future ahead, Frenelle is set to become a key player in advancing healthcare solutions worldwide.

Source link

Newsletter Updates

Enter your email address below and subscribe to our newsletter